Approved regimen
Approved labeled regimen
Product-, indication-, and jurisdiction-specific — see the monograph
- Product: Lutrepulse (gonadorelin acetate) 3.2 mg/vial lyophilised
- Route: Subcutaneous or intravenous via programmable pump
- Dosing: 5 µg every 90 minutes
- Response: Usually within 2-3 weeks
- Continue for 2 weeks after ovulation to support corpus luteum